Diligence memo · auto-generated · as of July 2, 2026
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Clene Nanomedicine, Inc. operates in Pharmaceuticals, based in SALT LAKE CITY.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Clene Nanomedicine, Inc. has raised $49M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $43M on 2020-08-10.
Most recent recorded round closed around 2020-08-10.
Valuation (modeled)modeled
Provath models Clene Nanomedicine, Inc. at approximately $1.4B (range $138M–$3.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.87× the median modeled value of Series C Pharmaceuticals companies in 2019–2021 (33 peers) — value vs value, same stage and era. Within the normal band (87% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 5.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 6.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 81% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Verastem, Inc., Sentia Wellness, Inc., Oyster Point Pharma, Inc., Terns Pharmaceuticals, Inc., Theseus Pharmaceuticals, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.